LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Inicio・Lista de Acciones・Kura Oncology Inc

Kura Oncology Inc

Cerrado

SectorSanidad

8.25 -2.14

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.17

Máximo

8.59

Métricas clave
By Trading Economics
Ingresos	-6.9M -81M
Ventas	-3.4M 17M
Margen de beneficios	-467.23
Empleados	260
EBITDA	-12M -86M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+235.4% upside

Dividendos
By Dow Jones
Próximas Ganancias	30 abr 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	16M 771M
Apertura anterior	10.39
Cierre anterior	8.25

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.575 / 6.6 Soporte y Resistencia

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 mar 2026, 17:19 UTC

Noticias de Eventos Importantes

Chubb to Assume Risk, Issue Policies for $20 Billion Strait of Hormuz Insurance Facility

20 mar 2026, 16:56 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: PMI Data to Show Middle East War's Impact on Sentiment

20 mar 2026, 16:56 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: PMI Data to Show Middle -2-

20 mar 2026, 16:45 UTC

Noticias de Eventos Importantes

The Week in Oil: U.S. Seeks to Ease Concerns Over War But Supply Risks Mount

20 mar 2026, 16:22 UTC

Noticias de Eventos Importantes

NYMEX Overview: Petroleum Futures Rise, Leaving Most Contracts on Track for Solid Weekly Gains -- OPIS

20 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

20 mar 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

20 mar 2026, 19:55 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Brent Crude Closes Out Volatile Week Higher -- Market Talk

20 mar 2026, 19:28 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Natural Gas Falls as Traders Sell Ahead of the Weekend -- Market Talk

20 mar 2026, 19:28 UTC

Adquisiciones, fusiones, absorciones

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

20 mar 2026, 18:39 UTC

Charlas de Mercado

Gold Settles With Largest Weekly Dollar Decline on Record -- Market Talk

20 mar 2026, 18:31 UTC

Adquisiciones, fusiones, absorciones

Honeywell Announces Pricing of Debt Tender Offers >HON

20 mar 2026, 18:19 UTC

Adquisiciones, fusiones, absorciones

Why Mayo and Soap No Longer Mix for Unilever -- Update

20 mar 2026, 18:15 UTC

Charlas de Mercado

iMarkets May Be Wrong in Pricing for Canadian Rate Increases -- Market Talk

20 mar 2026, 17:57 UTC

Charlas de Mercado

U.S. Oil Rig Count Inches Up -- Market Talk

20 mar 2026, 17:04 UTC

Noticias de Eventos Importantes

Chubb to Assume Risk, Issue Policies for $20B Strait of Hormuz Insurance Facility

20 mar 2026, 16:20 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

20 mar 2026, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

20 mar 2026, 15:40 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Unilever, McCormick Deal Makes Strategic Sense, But Risk Remains -- Market Talk

20 mar 2026, 15:30 UTC

Ganancias

Gemini Space Station's Earnings 'Better Than Feared.' Can They Save the Stock? -- Barrons.com

20 mar 2026, 15:26 UTC

Charlas de Mercado

Ganancias

Noticias de Eventos Importantes

Lands' End: War Impacts Weighing on Some European Consumers -- Market Talk

20 mar 2026, 15:26 UTC

Adquisiciones, fusiones, absorciones

Why Mayo and Soap No Longer Mix for Unilever -- WSJ

20 mar 2026, 15:25 UTC

Charlas de Mercado

Gilt Selloff Shows Vulnerability of U.K.'s Economy -- Market Talk

20 mar 2026, 15:19 UTC

Charlas de Mercado

Noticias de Eventos Importantes

UBS Raises Oil Price Forecast as Middle East Conflict Escalates -- Market Talk

20 mar 2026, 14:58 UTC

Noticias de Eventos Importantes

Chevron Jumps Into Top 20 Most Valuable U.S. Companies. The Iran War's Other Big Stock Movers. -- Barrons.com

20 mar 2026, 14:55 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Lower as Speculative Pullback Extends -- Market Talk

20 mar 2026, 14:54 UTC

Adquisiciones, fusiones, absorciones

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

20 mar 2026, 14:53 UTC

Adquisiciones, fusiones, absorciones

Unilever, McCormick Deal Would Create a New Condiment King -- WSJ

20 mar 2026, 14:46 UTC

Charlas de Mercado

U.K. Government Bonds Selloff More Pronounced Than Peers -- Market Talk

20 mar 2026, 14:45 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Price Forecasts For 2026-27 Raised at UBS -- Market Talk

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

235.4% repunte

Estimación a 12 Meses

Media 28.14 USD 235.4%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.575 / 6.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.